Cue Biopharma (CUE) Stock Price, Quote, News & History

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Name

Revenue

Change

Gross

Change

EBITDA

Change

EBIT

Change

Earnings

Change

About

Sector

Health Care

Industry

Biotechnology

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its...

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Bulls vs Bears

Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.

Benzinga

Benzinga

Cue Biopharma Inc (CUE) Stock Price, Quote, News & History

Key Statistics

Recent Cue Biopharma Inc News

PROCue Biopharma To Deliver Poster Presentation On Lead Asset, CUE-401, At World Immune Regulation Meeting 2026

PROCue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported

PROCue Biopharma Appoints Lucinda Warren Chief Financial And Business Officer, Effective Feb. 9

Financials

Cash Flows

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Compare

FAQ

How do I buy Cue Biopharma (CUE) stock?

Who are Cue Biopharma (CUE) competitors?

What is the forecast, or price target, for Cue Biopharma (CUE) stock?

What is the current price for Cue Biopharma (CUE)?

Does Cue Biopharma (CUE) pay a dividend?

When is Cue Biopharma (NASDAQ:CUE) reporting earnings?

Is Cue Biopharma (CUE) going to split?

What sector and industry does Cue Biopharma (CUE) operate in?

People Also Watch

Key Statistics

Recent Cue Biopharma Inc News

PROCue Biopharma To Deliver Poster Presentation On Lead Asset, CUE-401, At World Immune Regulation Meeting 2026

PROCue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported

PROCue Biopharma Appoints Lucinda Warren Chief Financial And Business Officer, Effective Feb. 9

Financials

Cash Flows

Analyst Rating and Forecast

Valuation Metrics

Company Debt

Key Statistics

About

Edge Rankings

Stock Score Locked: Want to See it?

Bulls vs Bears

Compare

FAQ

How do I buy Cue Biopharma (CUE) stock?

Who are Cue Biopharma (CUE) competitors?

What is the forecast, or price target, for Cue Biopharma (CUE) stock?

What is the current price for Cue Biopharma (CUE)?

Does Cue Biopharma (CUE) pay a dividend?

When is Cue Biopharma (NASDAQ:CUE) reporting earnings?

Is Cue Biopharma (CUE) going to split?

What sector and industry does Cue Biopharma (CUE) operate in?

People Also Watch

Bulls vs Bears

PRO
Cue Biopharma To Deliver Poster Presentation On Lead Asset, CUE-401, At World Immune Regulation Meeting 2026

PRO
Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported

PRO
Cue Biopharma Appoints Lucinda Warren Chief Financial And Business Officer, Effective Feb. 9

PRO
Cue Biopharma To Deliver Poster Presentation On Lead Asset, CUE-401, At World Immune Regulation Meeting 2026

PRO
Cue Biopharma Announces Data From CUE-401 Demonstrates All Dose Levels In Murine, NHP Trials Were Tolerated, No Adverse Events Reported

PRO
Cue Biopharma Appoints Lucinda Warren Chief Financial And Business Officer, Effective Feb. 9